Zhimin Xiao

Zhimin Xiao

Auto-generated profile, based on publicly available information

Zhimin Xiao

Sanofi US, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KLKaiwei Liang
Kaiwei Liang
LYLiuqing Yang
Liuqing Yang
CYChen Yin
Chen Yin
ZXZhimin Xiao
Zhimin Xiao
JZJunjian Zhang
Junjian Zhang
JHJian Huang
Jian Huang
Postmenopausal estrogen depletion is a characterized risk factor for Alzheimer disease (AD), a human disorder linked to high levels of β-amyloid peptide (Aβ) in brain tissue. Previous studies suggest that estrogen negatively regulates the level of Aβ in the brain, but the molecular mechanism is unknown. Here, we provide evidence that estrogen promotes Aβ degradation mainly through a principal Aβ degrading enzyme, neprilysin, in neuroblastoma SH-SY5Y cells. We also demonstrate that up-regulation of neprilysin by estrogen is dependent on both estrogen receptor α and β (ERα and ERβ), and ligand-activated ER regulates expression of neprilysin through physical interactions between ER and estrogen response elements (EREs) identified in the neprilysin gene. These results were confirmed by in vitro gel shift and in vivo chromatin immunoprecipitation analyses, which demonstrate specific binding of ERα and ERβ to two putative EREs in the neprilysin gene. The EREs also enhance ERα- and ERβ-dependent reporter gene expression in a yeast model system. Therefore, the study described here provides a putative mechanism by which estrogen positively regulates expression of neprilysin to promote degradation of Aβ, reducing risk for AD. These results may lead to novel approaches to prevent or treat AD.

1 December 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ZXZhimin Xiao
Zhimin Xiao
CHCan Huang
Can Huang
JWJun Wu
Jun Wu
LSLi Sun
Li Sun
WHWei Hao
Wei Hao
JHJian Huang
Jian Huang

6 January 2009 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
ZXZhi-Min Xiao
Zhi-Min Xiao
LSLi Sun
Li Sun
YLYu-Min Liu
Yu-Min Liu
JZJun-Jian Zhang
Jun-Jian Zhang
JHJian Huang
Jian Huang

29 December 2010 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
FSFei Shen
Fei Shen
KKKashif Z. Kirmani
Kashif Z. Kirmani
ZXZhimin Xiao
Zhimin Xiao
BTBenjamin H. Thirlby
Benjamin H. Thirlby
RHRobert J. Hickey
Robert J. Hickey
LMLinda H. Malkas
Linda H. Malkas

17 February 2020 in CARTILAGE
Verified
Journal Article
Open access
PDF file
KOKevin L. Ong
Kevin L. Ong
MRMaria Runa
Maria Runa
ZXZhimin Xiao
Zhimin Xiao
WNWilson Ngai
Wilson Ngai
ELEdmund Lau
Edmund Lau
RARoy D. Altman
Roy D. Altman
Concerns have been raised about severe acute localized reactions (SALR) following intra-articular (IA) hyaluronic acid (HA) injections for knee osteoarthritis (OA). We compared surrogate SALR measures between hylan G-F 20 and non-hylan G-F 20 HA patients and evaluated corresponding SALR risk factors for hylan G-F 20 patients. Knee OA patients were identified from the Optum Clinformatics dataset (January 2006 to June 2016), stratified into hylan G-F 20 and non-hylan G-F 20 HA users. Occurrences of surrogate SALR measures including inflammation/infection, intra-articular corticosteroid (CS) injections, arthrocentesis/aspiration, and office visits were evaluated within 3 days of HA use. Risk factors were evaluated using logistic regression. The cohort involved 748,428 HA patients (23.2% in the hylan G-F 20 group). Inflammation/infection rate was 0.001% for hylan G-F 20 and 0.002% for non-hylan G-F 20 HA groups. Risk of CS injection (any diagnosis) was greater for hylan G-F 20 patients by 28% (P < 0.001). Combined rates of CS injection and arthrocentesis/aspiration (any diagnosis) were comparable for both groups (hylan G-F 20, 2.2%; non-hylan G-F 20 HA, 2.6%). The risk of any visit or studied responses was lower for the hylan G-F 20 cohort by 12% (P < 0.001). Clinical characteristics, such as CS injections within 1 week before HA and fluoroscopic imaging, were associated with the outcomes. The diagnosis of inflammations or infections within 3 days of the HA injection was extremely rare. The overall risk of surrogate SALR measures was similar for hylan G-F 20 and non-hylan G-F 20 HA patients.

27 August 2008 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
KLKaiwei Liang
Kaiwei Liang
LYLiuqing Yang
Liuqing Yang
ZXZhimin Xiao
Zhimin Xiao
JHJian Huang
Jian Huang